Abstract
Melphalan in combination with glucocorticoid steroids has been an important first-line treatment option for multiple myeloma (MM) for over 40 years, but response rates have been only 50-60%, with less than 5% complete remissions (CRs). More intensive combinations of chemotherapy such as vincristine, Adriamycin and Dexamethasone (Dex) (VAD) improved objective response rates to 40%-70%, with 10-17% complete responses, but overall survival (OS) was not significantly improved. High-dose therapy with autologous hematopoietic stem cell transplantation (AHCT) has improved OS by approximately 12 months in three prospective randomized trials, but is not available to many patients. More recently, novel therapies thalidomide, the immunomodulatory thalidomide analogue Revlimid, and the proteasome inhibitor bortezomib have demonstrated significant activity to overcome drug resistance in patients with relapsed and refractory MM. Early results indicate that these novel therapeutics have even more impressive activity in combination with conventional therapies prior to AHCT, as well as following AHCT. Furthermore, these novel therapies should be more widely available to most patients with MM.
Keywords: cyclophosphamide, Erythropoietin, Tandem Transplantation, Allografting, thalidomide, Proteasome Inhibitors
Current Cancer Therapy Reviews
Title: Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies
Volume: 2 Issue: 2
Author(s): Laurence Catley and Kenneth C. Anderson
Affiliation:
Keywords: cyclophosphamide, Erythropoietin, Tandem Transplantation, Allografting, thalidomide, Proteasome Inhibitors
Abstract: Melphalan in combination with glucocorticoid steroids has been an important first-line treatment option for multiple myeloma (MM) for over 40 years, but response rates have been only 50-60%, with less than 5% complete remissions (CRs). More intensive combinations of chemotherapy such as vincristine, Adriamycin and Dexamethasone (Dex) (VAD) improved objective response rates to 40%-70%, with 10-17% complete responses, but overall survival (OS) was not significantly improved. High-dose therapy with autologous hematopoietic stem cell transplantation (AHCT) has improved OS by approximately 12 months in three prospective randomized trials, but is not available to many patients. More recently, novel therapies thalidomide, the immunomodulatory thalidomide analogue Revlimid, and the proteasome inhibitor bortezomib have demonstrated significant activity to overcome drug resistance in patients with relapsed and refractory MM. Early results indicate that these novel therapeutics have even more impressive activity in combination with conventional therapies prior to AHCT, as well as following AHCT. Furthermore, these novel therapies should be more widely available to most patients with MM.
Export Options
About this article
Cite this article as:
Catley Laurence and Anderson C. Kenneth, Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872807
DOI https://dx.doi.org/10.2174/157339406776872807 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Measurement of Hemodynamic Parameters and Antidepressant Activity in Hypertensive Rats Following Two Weeks Consumption of <i>Acacia Tortilis</i> Leaves Extract
The Natural Products Journal Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Noninvasive Monitoring of Intracranial Pressure
Recent Patents on Biomedical Engineering (Discontinued) Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature
Inflammation & Allergy - Drug Targets (Discontinued) Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology